Search

Search Funnelback University

Search powered by Funnelback
10 results 20 results 50 results
Relevance Date (Newest first) Date (Oldest first) Title (A-Z) Title (Z-A) Distance URL (A-Z) URL (Z-A) Shuffle
141 - 160 of 218 search results for `Research news` |u:www-neurosciences.medschl.cam.ac.uk

  1. Fully-matching results

  2. Our People - Cambridge Clinical Multiple Sclerosis Research

    https://www-neurosciences.medschl.cam.ac.uk/cambridge-clinical-ms-research/our-people/
    23 Feb 2024: Declan Chard, Principal Clinical Research Associate at UCL Queen Square Institute of Neurology. ... Tomas Kalincik, Professor, Head of the Clinical Outcomes Research (CORe) Unit, University of Melbourne.

  3. Alemtuzumab and blood transfusion: irradiation not needed - Cambridge …

    https://www-neurosciences.medschl.cam.ac.uk/cambridge-clinical-ms-research/alemtuzumab-and-blood-transfusion-irradiation-not-needed/
    23 Feb 2024: Cambridge Clinical Multiple Sclerosis Research. News. Alemtuzumab and blood transfusion: irradiation not needed.

  4. Clinical Remyelination Research (Cunniffe Group) - Cambridge Clinical …

    https://www-neurosciences.medschl.cam.ac.uk/cambridge-clinical-ms-research/people/clinical-remyelination-research-group/
    23 Feb 2024: We take scientific research from the laboratory to the bedside, and conduct clinical trials of drugs that we believe will promote remyelination in people with MS. ... She has a background in translational biomedical research, and has worked in industry

  5. Remyelination varies markedly within and between lesions - Cambridge…

    https://www-neurosciences.medschl.cam.ac.uk/cambridge-clinical-ms-research/remyelination-varies-markedly-within-and-between-lesions/
    23 Feb 2024: Cambridge Clinical Multiple Sclerosis Research. News. Remyelination varies markedly within and between lesions.

  6. Natalia Malig

    https://www-neurosciences.medschl.cam.ac.uk/horvathlab/natalia-malig/
    23 Feb 2024: Horvath Laboratory. Natalia Malig. Natalia Malig. Research Assistant. Natalia is a Research Assistant in the group of prof. ... Hannah Monyer at DKFZ. Ever since, she has a strong interest in the topic and aspires to continue research as an MPhil student.

  7. Scientists identify first genetic marker for MS severity - Department …

    https://www-neurosciences.medschl.cam.ac.uk/blog/scientists-identify-first-genetic-marker-for-ms-severity/
    23 Feb 2024: Department of Clinical Neurosciences. Featured news. Scientists identify first genetic marker for MS severity. ... Studying the genetics of multiple sclerosis has been a major theme of neurological research in Cambridge since the late 1980s.

  8. EMA announces temporary restriction on alemtuzumab prescribing -…

    https://www-neurosciences.medschl.cam.ac.uk/cambridge-clinical-ms-research/ema-announces-temporary-restriction-on-alemtuzumab-prescribing/
    23 Feb 2024: Cambridge Clinical Multiple Sclerosis Research. News. EMA announces temporary restriction on alemtuzumab prescribing. ... We will see what the final opinion is! Filed Under: News.

  9. Association of British Neurologists advice on DMT use during COVID -…

    https://www-neurosciences.medschl.cam.ac.uk/cambridge-clinical-ms-research/association-of-british-neurologists-advice-on-dmt-use-during-covid/
    23 Feb 2024: Cambridge Clinical Multiple Sclerosis Research. News. Association of British Neurologists advice on DMT use during COVID.

  10. New genetic clues point to new treatments for ‘silent’ stroke -…

    https://www-neurosciences.medschl.cam.ac.uk/blog/new-genetic-clues-point-to-new-treatments-for-silent-stroke/
    23 Feb 2024: Department of Clinical Neurosciences. Featured news. New genetic clues point to new treatments for ‘silent’ stroke. ... This research provides real hope that we can prevent and treat this devastating type of stroke much better in the.

  11. Other inherited neurodegenerative disorders’ patient organisations

    https://www-neurosciences.medschl.cam.ac.uk/mitocamb/resources/patient-organisations/other-inherited-neurodegenerative-disorders-patient-organisations/
    23 Feb 2024: They fund research into finding treatments and cures, and offer advice, information and support to people affected by the condition. ... They support high quality research to find effective treatments and cures for all muscle-wasting conditions.

  12. A Trial of Bexarotene in Multiple Sclerosis [CCMR One] - Cambridge…

    https://www-neurosciences.medschl.cam.ac.uk/cambridge-clinical-ms-research/a-trial-of-bexarotene-in-multiple-sclerosis-ccmr-one/
    23 Feb 2024: Cambridge Clinical Multiple Sclerosis Research. A Trial of Bexarotene in Multiple Sclerosis [CCMR One].

  13. MS Society Press Release on the bexarotene trial - Cambridge Clinical …

    https://www-neurosciences.medschl.cam.ac.uk/cambridge-clinical-ms-research/ms-society-press-release-on-the-bexarotene-trial/
    23 Feb 2024: Cambridge Clinical Multiple Sclerosis Research. News. MS Society Press Release on the bexarotene trial. ... This new research is a major milestone in our plan to stop MS and we’re incredibly excited about the potential it’s shown for future studies.

  14. Personalised Treatments in Multiple Sclerosis (Brown Group) -…

    https://www-neurosciences.medschl.cam.ac.uk/cambridge-clinical-ms-research/people/personalised-treatments-in-multiple-sclerosis-group/
    23 Feb 2024: Nadira Fernando. Research Assistant. Nadira is a research assistant in the Brown Group. ... Jacky Porter. Clinical Research Manager. Jacky is clinical research manager for the Brown group.

  15. Leading Cambridge neuroscientist appointed as Executive Chair of…

    https://www-neurosciences.medschl.cam.ac.uk/blog/leading-cambridge-neuroscientist-appointed-as-executive-chair-of-medical-research-council/
    23 Feb 2024: Site Search. Leading Cambridge neuroscientist appointed as Executive Chair of Medical Research Council. ... Department of Clinical Neurosciences. Featured news. Leading Cambridge neuroscientist appointed as Executive Chair of Medical Research Council.

  16. Apathy could predict onset of dementia years before other symptoms -…

    https://www-neurosciences.medschl.cam.ac.uk/blog/apathy-could-predict-onset-of-dementia-years-before-other-symptoms/
    23 Feb 2024: Department of Clinical Neurosciences. Featured news. Apathy could predict onset of dementia years before other symptoms. ... The research was largely funded by the Medical Research Council, Wellcome, and the National Institute for Health Research.

  17. CCMR2: A Trial of Metformin and Clemastine as Remyelinating Drugs in…

    https://www-neurosciences.medschl.cam.ac.uk/cambridge-clinical-ms-research/ccmr2-a-trial-of-metormin-and-clemastine-as-remyelinating-drugs-in-ms/
    23 Feb 2024: Cambridge Clinical Multiple Sclerosis Research. CCMR2: A Trial of Metformin and Clemastine as Remyelinating Drugs in MS. ... Alasdair Coles, February 2023. This trial has been approved by a Research Ethics Committee:.

  18. ORION: Outcomes Research in Inherited Optic Neuropathies

    https://www-neurosciences.medschl.cam.ac.uk/mitocamb/our-research-2/research-studies/understanding-studies/orion-outcomes-research-in-inherited-optic-neuropathies/
    23 Feb 2024: This information will be used to form the basis of clinical trials, helping progress research towards a curative therapy for inherited optic neuropathies. ... Research aims:. The aim of this study is to understand how inherited optic neuropathies

  19. Long term follow-up from phase 3 alemtuzumab trials: 11-13 years…

    https://www-neurosciences.medschl.cam.ac.uk/cambridge-clinical-ms-research/long-term-follow-up-from-phase-3-alemtuzumab-trials-11-13-years-after-first-dosing/
    23 Feb 2024: Cambridge Clinical Multiple Sclerosis Research. News. Long term follow-up from phase 3 alemtuzumab trials: 11-13 years after first dosing! ... Coles Ther Adv Neurol Disord 2023, Vol. 16: 1–16. Filed Under: News.

  20. Trial REadiness in Ataxia Telangiectasia (TREAT-AT)

    https://www-neurosciences.medschl.cam.ac.uk/mitocamb/our-research-2/research-studies/understanding-studies/trial-readiness-in-ataxia-telangiectasia-treat-at/
    23 Feb 2024: The aim of this study therefore, is to assess the neurological progression of Ataxia-Telangiectasia and to select the best outcome measure for a future clinical trial, helping progress research towards ... Research aims:. The aim of this study is to

  21. Research projects

    https://www-neurosciences.medschl.cam.ac.uk/sound-lab/research/publications-2/
    23 Feb 2024: SOUND Laboratory. Research projects. MRC Senior Fellowship Hearing Research (MR/S002537/1). Developing electrophysiological measures of brain activity to optimise cochlear implant (CI) outcomes. ... The BEARS project is funded by the National Institute

Refine your results

clear all

Date

Search history

Recently clicked results

Recently clicked results

Your click history is empty.

Recent searches

Recent searches

Your search history is empty.